Royal Capital Wealth Management’s Biogen BIIB Stock Holding History

Royal Capital Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,266	Closed	-$328K	–	96
2023 Q4	$328K	Sell	1,266 -29	-2%	-$7.12K	0.28%	63
2023 Q3	$333K	Hold	1,295	–	–	0.32%	59
2023 Q2	$369K	Hold	1,295	–	–	0.35%	58
2023 Q1	$360K	Sell	1,295 -16	-1%	-$4.43K	0.36%	59
2022 Q4	$363K	Hold	1,311	–	–	0.39%	56
2022 Q3	$350K	Hold	1,311	–	–	0.41%	57
2022 Q2	$267K	Sell	1,311 -180	-12%	-$36.8K	0.29%	73
2022 Q1	$314K	Sell	1,491 -4	-0.3%	-$870	0.31%	73
2021 Q4	$359K	Buy	+1,495	New	+$384K	0.35%	68

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Capital Wealth Management's BIIB Position: Q1 2024 in Review

Royal Capital Wealth Management sold out of Biogen (BIIB) in Q1 2024, closing a stake of 1,266 shares — an estimated $328K sold.

Royal Capital Wealth Management first reported a position in BIIB in Q4 2021 and held it in 9 quarters. The position peaked at $369K in Q2 2023. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Royal Capital Wealth Management reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Royal Capital Wealth Management sold 1,266 Biogen shares in Q1 2024, an estimated $328K.
Royal Capital Wealth Management first reported a position in Biogen in Q4 2021 and held it in 9 quarters.
Royal Capital Wealth Management's Biogen position peaked at $369K in Q2 2023.
955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Royal Capital Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.